Clinical application of cancer therapy targeting newly discovered T-cell inhibitory pathways

Research Project

Project/Area Number	24791443
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Digestive surgery
Research Institution	Nara Medical University
Principal Investigator	MIGITA Kazuhiro 奈良県立医科大学, 医学部附属病院, 研究員 (40570990)
Project Period (FY)	2012-04-01 – 2014-03-31
Project Status	Completed (Fiscal Year 2013)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000) Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords	食道癌 / 免疫療法 / HVEM / 癌免疫療法
Research Abstract	We investigated the functions of herpesvirus entry mediator (HVEM) in vitro and in vivo using the small interfering RNA (siRNA) silencing technique. HVEM gene silencing significantly inhibited cancer cell proliferation through cell cycle arrest in vitro. HVME gene silencing significantly inhibited tumor growth in mice models. The percentage of Ki-67-positive cells was found to be significantly decreased in tumors treated with HVEM siRNA compared with control specimens. In tumors treated with HVEM siRNA, CD8+ lymphocytes infiltrating into the surrounding are of the tumor were found to be significantly more abundant compared with control specimens. The antitumor effect of HVEM blockade was associated with reduced cell proliferation activity and the induction of CD8+ cells.

Report

(3 results)